AUS
NZ
UK
CA
USA
IND
Highlights
- Island Pharmaceuticals reports positive Phase 2a trial results for ISLA-101.
- Evidence of anti-viral activity and safety profile established in dengue fever trial.
- Next phase to investigate therapeutic benefits in infected individuals.
Island Pharmaceuticals (ASX:ILA) has announced encouraging findings from its PROTECT Phase 2a/b trial for the investigational drug ISLA-101, targeting dengue fever. The results showcase the drug’s safety and its potential antiviral activity, marking a significant step in the fight against the mosquito-borne disease.
The Phase 2a segment of the trial tested ISLA-101’s ability to prevent or reduce viremia, a condition where viruses enter the bloodstream, and its effectiveness in minimizing symptoms compared to a placebo. Participants received the drug prophylactically before being exposed to a weakened dengue virus strain, specially developed by the US Army.
Key Findings from the Trial
The trial’s safety review committee (SRC) confirmed that ISLA-101 achieved its therapeutic concentration in the blood of some participants, validating the drug's dosing parameters. This outcome builds on dose-finding work and in silico modeling conducted during and after earlier single ascending dose studies.
Importantly, SRC reported a reduction in viral load among individuals treated with ISLA-101, providing evidence of its antiviral potential. The SRC unanimously agreed there were no safety concerns with the drug and recommended proceeding to the therapeutic Phase 2b cohort.
The next stage of the trial aims to evaluate ISLA-101’s efficacy in reducing symptoms in individuals already infected with the dengue virus, a critical step in advancing the drug's therapeutic application.
Milestone for Island Pharmaceuticals
The trial’s positive findings are a significant milestone for Island Pharmaceuticals. Managing Director Dr. David Foster highlighted this achievement as a standout moment for the company. While blinded to the full dataset, the unblinded SRC confirmed the drug’s safety and preliminary efficacy. Dr. Foster expressed optimism about the trial's progress and its potential impact on dengue treatment.
Scientific Endorsement
Island’s scientific advisory board member Stephen Thomas emphasized the importance of completing the interim review process. He called the SRC’s recommendation to move to the next trial phase a crucial advancement in understanding ISLA-101’s role in addressing dengue disease. The forthcoming therapeutic phase is expected to provide deeper insights into the drug’s ability to mitigate symptoms in infected individuals.
The promising results from ISLA-101 represent a significant development in tackling dengue fever, paving the way for continued research and progress in combating this global health challenge.
